Skip to main content

Table 1 Clinical characteristics of 416 NSCLC patients treated with EGFR-TKIs

From: Identification of genetic alterations associated with primary resistance to EGFR-TKIs in advanced non-small-cell lung cancer patients with EGFR sensitive mutations

Variables

Patients

EGFR mutation

EGFR copy number

n = 416

Mutant

Wild

 

FISH (+)

FISH (−)

 

No.

%

n = 169

n = 247

P value

n = 167

n = 249

P value

Age groups

 ≤ 60

264

63.5

108 (63.9)

156 (63.2)

0.918

108 (64.7)

156 (62.7)

0.680

 > 60

152

36.5

61 (36.1)

91 (36.8)

59 (35.3)

93 (37.3)

Gender

 Male

253

60.8

86 (50.9)

167 (67.6)

< 0.001

92 (55.1)

161 (64.7)

0.052

 Female

163

39.2

83 (49.1)

80 (32.4)

75 (44.9)

88 (35.3)

Smoking status

 Never-smoker

269

64.7

129 (76.3)

140 (56.7)

< 0.001

116 (69.5)

155 (62.2)

0.142

 Smoker

147

35.3

40 (23.7)

107 (43.3)

51 (30.5)

94 (37.8)

Histology

 ADC

336

80.8

154 (91.1)

182 (73.7)

< 0.001

138 (82.6)

198 (79.5)

0.449

 Non-ADC

80

19.2

15 (8.9)

65 (26.3)

29 (17.4)

51 (20.5)

Differentiation

 High to medium

185

44.5

92 (54.4)

93 (37.7)

< 0.001

85 (50.9)

100 (40.2)

0.035

 Low

231

55.5

77 (45.6)

154 (62.3)

82 (49.1)

149 (59.8)

Disease stage

 Recurrent

128

30.8

55 (32.5)

73 (29.6)

0.127

51 (30.5)

77 (30.9)

0.926

 IIIb

73

17.5

22 (13.0)

51 (20.6)

28 (16.8)

45 (18.1)

 IV

215

51.7

92 (54.4)

123 (49.8)

88 (52.7)

127 (51.0)

Clinical response

 CR + PR

93

22.4

68 (40.2)

25 (10.1)

< 0.001

53 (31.7)

40 (16.1)

< 0.001

 SD

158

38.0

83 (49.1)

75 (30.4)

79 (47.3)

79 (31.7)

 PD

161

38.7

14 (8.3)

147 (59.5)

32 (19.2)

129 (51.8)

 Unknown

4

1.0

4 (2.4)

0 (0.0)

3 (1.8)

1 (0.4)

Line of EGFR-TKIs

 First

104

25.0

62 (36.7)

42 (17.0)

< 0.001

48 (28.7)

56 (22.5)

< 0.001

 Second

217

52.2

107 (63.3)

110 (44.5)

97 (58.1)

120 (48.2)

 Higher

95

22.8

0 (0.0)

95 (38.5)

22 (13.2)

73 (29.3)

  1. Non-adenocarcinoma included squamous-cell carcinoma (n = 58), adenosquamous cell carcinoma (n = 20), and other histology (n = 2)
  2. ADC adenocarcinoma, FISH fluorescent in situ hybridization, CR complete remission, PR partial remission, SD stable disease, PD progressive disease, TKI, tyrosine kinase inhibitor